FDA approves new treatment option for patients with HER2-positive breast cancer who have progressed on available therapies

MS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body.
"Today's approval provides additional hope to the 100,000 people in the U.S., and the more than 20 million globally, who live with this debilitating blood disorder," said Acting FDA Commissioner Adm. Brett P. Giroir, M.D.